AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biohit Oyj

Declaration of Voting Results & Voting Rights Announcements Mar 20, 2014

3304_dva_2014-03-20_d68436a2-155e-4fca-ac25-1bd99b218e17.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Disclosure 313753

Biohit Oyj - Total number of voting rights and capital

Increased number of Biohit shares entered into trade register

Biohit Oyj Stock Exchange Release March 20, 2014 at 9:30 a.m. local time (EET) New B-share subscriptions, total 15.000 pcs, based on the company's stock option program II 2013 approved by the Board of Directors of Biohit Oyj, have been entered into the trade register today. The share subscription price was three (3) euros per share. The nominal value of the share, 2.550 euros, will be recorded in equity and the rest (42.450 euros) in the invested unrestricted equity fund. After the subscriptions (15.000 shares), the number of all Biohit Oyj's shares will rise into 13.825.593 shares (13.810.593) and B-shares will rise into 10.850.093 shares (10.835.093). The company's share capital will increase to 2,350,350.81 euros to from 2,347,800.81 euros. The new shares will correspond to a percentage of 0.1% of the Biohit Oyj's total number of shares and 0.02% of the share of voting rights after registration. Biohit Oyj has applied for the listing of its new shares on the NASDAQ OMX Helsinki in the same series as the company's existing shares. The new shares will be listed on March 21, 2014. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 [email protected] www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is “Innovating for Health” - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com.

Talk to a Data Expert

Have a question? We'll get back to you promptly.